Cellyan Biotechnology Co

Cellyan Biotechnology Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cellyan Biotechnology Co (HKPD) as of Oct 18, 2026 is -994,902.00 USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 133,779.00 USD — a change of -843.69% (lower).

EBITDA

-994,902.00USD

YoY

-843.69%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cellyan Biotechnology Co is 2026 -994,902.00 USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cellyan Biotechnology Co was 2025 133,779.00 USD. It decreases by -843.69% lower compared to the previous year.

The Cellyan Biotechnology Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2023
1.04 M USD
Jan 1, 2024
1.61 M USD
Jan 1, 2025
133,779.00 USD
Jan 1, 2026
-994,902.00 USD
The Cellyan Biotechnology Co EBITDA history
YEAREBITDAYoY
-994,902.00USD-843.69%
133,779.00USD-91.68%
1.61 MUSD+54.08%
1.04 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cellyan Biotechnology Co Stock analysis

What does Cellyan Biotechnology Co do? Cellyan Biotechnology Co Ltd, with ticker HKPD and ISIN KYG6365B1041, is a company based in Hong Kong. The company operates within the Industrials sector, specifically in the Logistics & Transportation industry. Cellyan Biotechnology is set to have its IPO on January 15, 2025. The company's website is listed as http://www.9zt.hk/. The provided source description, which is treated as untrusted, mentions Hong Kong Pharma Digital Technology Holdings Ltd, but this appears to be a different entity. The source incorrectly attributes to Cellyan Biotechnology a focus on OTC pharmaceutical business, supply chain services, and procurement and distribution services related to pharmaceuticals. However, these details are not confirmed for Cellyan Biotechnology Co Ltd and should not be included in the factual profile. The company's city of operation is listed as unknown, and no additional details about its founding year, key personnel, acquisitions, or specific products are provided. The company's operational focus remains within the logistics and transportation sector, with no further specifics available beyond the IPO date and website. The source description's reference to pharmaceuticals is inconsistent with the company's actual sector and industry, and thus is disregarded as unverified information. Cellyan Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellyan Biotechnology Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cellyan Biotechnology Co is -994,902.00 USD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cellyan Biotechnology Co changed from 133,779.00 USD to -994,902.00 USD, representing a -843.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Cellyan Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Cellyan Biotechnology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Cellyan Biotechnology Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Cellyan Biotechnology Co